Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...